Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer

Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer

Saved in:

Bibliographic Details
Main Authors:	Raza Ur Rehman, MBBS, Ahmad Furqan Anjum, MBBS, Rida Fatima, MBBS
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Current Therapeutic Research
Subjects:	Bispecific T-cell engager DLL3 protein FDA approval Immunotherapy Small cell Lung cancer (SCLC) Tarlatamab
Online Access:	http://www.sciencedirect.com/science/article/pii/S0011393X24000432
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer
by: Kangkang Ji, et al.
Published: (2025-05-01)

First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report
by: Alissa J. Cooper, MD, et al.
Published: (2024-12-01)

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
by: Prajwol Shrestha, et al.
Published: (2025-07-01)

Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer
by: Ke Zhao, et al.
Published: (2025-03-01)

A year in review: new treatments and expanded indications in dermatology in 2024
by: Lauren N. McGrath, et al.
Published: (2025-12-01)

Bispecific antibodies: unleashing a new era in oncology treatment
by: Lin Shui, et al.
Published: (2025-08-01)

A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited‐Stage Small Cell Lung Cancer
by: Fan Ge, et al.
Published: (2025-08-01)

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer
by: Jing Cheng, et al.
Published: (2025-02-01)

Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report
by: Aditi Singh, MBBS, MPH, et al.
Published: (2025-06-01)

2024 FDA TIDES (Peptides and Oligonucleotides) Harvest
by: Othman Al Musaimi, et al.
Published: (2025-02-01)

Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database
by: Dipesh Uprety, et al.
Published: (2025-02-01)

Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment
by: Lauren C. Naatz, et al.
Published: (2025-03-01)

Engineering Bifunctional Calcium Alendronate Gene‐Delivery Nanoneedle for Synergistic Chemo/Immuno‐Therapy Against HER2 Positive Ovarian Cancer
by: Guochuang Chen, et al.
Published: (2023-05-01)

Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
by: Emily Wolf, et al.
Published: (2025-01-01)

Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review
by: Torchia A, et al.
Published: (2025-04-01)

Atezolizumab in the treatment of small cell lung cancer
by: Kacper Ordon, et al.
Published: (2025-06-01)

A Search for FDA Approved Drugs with Multiple Antiemetic Targets: A Computational-Based Drug Repositioning Study
by: Abdulmajeed Yunusa*1, Albashir Tahir1,2
Published: (2025-05-01)

Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report
by: Heng-Xu Lyu, et al.
Published: (2024-09-01)

Cadonilimab as second-line therapy in immunotherapy-resistant squamous NSCLC: a case report and review
by: Shuo Qiu, et al.
Published: (2025-07-01)

Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in small cell lung cancer
by: Xin Wang, et al.
Published: (2025-05-01)

Tracking protein kinase targeting advances: integrating QSAR into machine learning for kinase-targeted drug discovery
by: Rand Shahin, et al.
Published: (2025-12-01)

Chemoradiotherapy followed by continued immunotherapy for out-of-field progression during consolidation in limited-stage SCLC: a case report
by: Ying Jiang, et al.
Published: (2025-07-01)

Bladder cancer biomarkers: current approaches and future directions
by: Melika Ahangar, et al.
Published: (2024-11-01)

Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies
by: Idil Hutter-Karakoc, et al.
Published: (2025-12-01)

Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC
by: Qianqian Zhang, et al.
Published: (2025-05-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01)

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19
by: Edward Richardson, et al.
Published: (2025-07-01)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
by: Yinghui Xu, et al.
Published: (2023-02-01)

A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational Study
by: Ajay Kumar Shukla, et al.
Published: (2025-01-01)

A Computational Study of Efficient Combinations of FDA-Approved Drugs and Dietary Supplements in Endometrial Cancer
by: Madhurima Mondal, et al.
Published: (2024-01-01)

Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
by: Jia Yu, et al.
Published: (2025-08-01)

In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
by: Ridwan Abiodun Salaam, et al.
Published: (2025-03-01)

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents
by: Ute Hennrich, et al.
Published: (2025-06-01)

Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases <i>Pseudomonas aeruginosa</i> Tolerance to Ciprofloxacin
by: Yael Schlichter Kadosh, et al.
Published: (2024-11-01)

FDA approves leniolisib (Joenja) as the first treatment for APDS: A breaththrough in the field of immunology
by: Muhammad Talha, et al.
Published: (2024-01-01)

How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD
by: Steven E. Nissen, et al.
Published: (2022-12-01)

Nanobody‐mediated complement activation to kill HIV‐infected cells
by: Maria Lange Pedersen, et al.
Published: (2023-02-01)

Sinonasal small-cell carcinoma combined concurrently with small-cell lung carcinoma: case report and literature review
by: Rencui Quan, et al.
Published: (2025-01-01)

PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY
by: A. V. Rudakova, et al.
Published: (2017-08-01)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
by: Joshua D Freedman, et al.
Published: (2017-06-01)